Prelude Therapeutics (PRLD) EBIT (2019 - 2026)
Prelude Therapeutics (PRLD) reported EBIT of -$14.2 million for Q1 2026, up 59.03% on a YoY basis from -$8.9 million in Q1 2025, and up 18.28% sequentially from -$17.3 million in Q4 2025.
Prelude Therapeutics (PRLD) EBIT (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of EBIT data on file, last reported at -$14.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 59.03% year-over-year to -$14.2 million; the trailing twelve-month figure through Mar 2026 stood at -$84.1 million (up 39.89% YoY), and the FY2025 full-year result was -$104.6 million, up 25.16% from the prior year.
- EBIT advanced to -$14.2 million in Q1 2026, from -$17.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$14.2 million in Q1 2026 to a low of -$37.4 million in Q4 2023.
- A 5-year average of -$30.3 million and a median of -$32.4 million in 2023 frame the typical range for EBIT.
- Across the five-year window, EBIT slumped 37.88% in 2022 and jumped 59.03% in 2026, its largest moves.
- Tracing PRLD's EBIT over 5 years: stood at -$33.4 million in 2022, then decreased by 11.96% to -$37.4 million in 2023, then grew by 9.49% to -$33.8 million in 2024, then surged by 48.72% to -$17.3 million in 2025, then climbed by 18.28% to -$14.2 million in 2026.
- Business Quant data shows PRLD's EBIT at -$14.2 million in Q1 2026, -$17.3 million in Q4 2025, and -$20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -14.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.18 Mn |
| Dec 31, 2025 | -17.35 Mn |
| Sep 30, 2025 | -20.42 Mn |
| Jun 30, 2025 | -32.19 Mn |
| Mar 31, 2025 | -34.61 Mn |
| Dec 31, 2024 | -33.83 Mn |
| Sep 30, 2024 | -34.38 Mn |
| Jun 30, 2024 | -37.16 Mn |
| Mar 31, 2024 | -34.34 Mn |
| Dec 31, 2023 | -37.38 Mn |
| Sep 30, 2023 | -33.39 Mn |
| Jun 30, 2023 | -32.40 Mn |
| Mar 31, 2023 | -29.12 Mn |
| Dec 31, 2022 | -33.39 Mn |
| Sep 30, 2022 | -30.41 Mn |
| Jun 30, 2022 | -29.46 Mn |
| Mar 31, 2022 | -30.29 Mn |
| Dec 31, 2021 | -33.01 Mn |
| Sep 30, 2021 | -30.84 Mn |
| Jun 30, 2021 | -27.92 Mn |